Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence

PURPOSE: We developed an unbiased framework to study the association of several mutations in predicting resistance to hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS), analogous to consumer and commercial recommender systems in which customers who bought products A and...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JCO Precis Oncol
Prif Awduron: Nazha, Aziz, Sekeres, Mikkael A., Bejar, Rafael, Rauh, Michael J., Othus, Megan, Komrokji, Rami S., Barnard, John, Hilton, Cameron B., Kerr, Cassandra M., Steensma, David P., DeZern, Amy, Roboz, Gail, Garcia-Manero, Guillermo, Erba, Harry, Ebert, Benjamin L., Maciejewski, Jaroslaw P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2019
Pynciau:
Original Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6818517/
https://ncbi.nlm.nih.gov/pubmed/31663066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.19.00119
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg